Melanoma Patient Network Europe
MPNE 2019 22nd- 24th March 2019
As you know
we work best under pressure ;-)
22nd- 24th March 2019
arrival 22nd in the morning, we start early in the afternoon
NH Hotel BLOOM
Rue Royale - Koningsstraat, 250, 1210 Brussels, Belgium
Planning meeting ECAB (internal)
Thursday, 14.00- 18.00
MPNEhubs- invitation only
Thursday, 21st March
19.30 MPNE hubs working dinner
Friday, 22nd March
8.00- 12.00 MPNEhubs
Friday, 22nd March
1.1 QuickStart to MPNE2019, especially recommended for MPNE new-comers
The goal of this session is to make sure that everyone has the necessary knowledge to follow the rest of the weekend and we recommend every new-comer to attend.
We do appreciate that also everyone else wants to make sure they REALLY have the Melanoma basics. However, if you have already attended a number of QuickStarts- this will be like the one you attended at your first visit.
We obviously continuously tweak and refine the content to be even clearer and more memorable- feel free to copy for your own conferences- but please, don't send us another feed-back 'This was just like last time, I already knew all of this?'- because that is JUST the intention!
Welcome to the conference and MPNE
Melanoma in a nutshell
Know your stage!
The Melanoma stage defines treatment options and prognosis, so is critical to understand. This is the compressed MPNE version on staging!
Violeta Astratinei and Gilly Spurrier, MPNE
MPNE 2019- the short version
What to expect from this weekend with brief introduction to sessions
Fredrik Östman and Bettina Ryll, MPNE
1.2 QuickStart Ocular Melanoma: parallel
Anatomy of the Eye
Guilherme Neri Peris and Martina Rooijakkers
Meet your colleagues, also time to think and hang your posters!
Parallel session and workshop program: please do not forget to submit your choices!
Workshop program here
Advocacy Speed Dating with Kacie
For those of you who are already getting worried- our advocacy speed dating is the most fast & fun way to get to talk Melanoma advocacy to a large number of people in a very short amount of time.
Coming for the first time? You'll have met the Melanoma advocate 'dinos' by the end of the session!
Been here many times before? You will know who is new, have heard some new perspectives and know whom to help!
20:00 Welcome Dinner
Saturday, 23rd March
8.00- 9.00 Breakfast
Session- thinking about resistance
On our forums, we regularly see patients who want to believe that the initial impressive results to targeted therapy (BRAFi and MEKi inhibitors) are permanent- and who are distraught and unprepared when resistance sets in. Patients are equally disappointed when immune therapy, hailed as the new 'cancer cure', does not work for them.
Understand the concepts of primary, acquired and reversible resistance and the current thinking about strategies how to overcome those. What are the next promising treatments in the pipeline?
Introduction to the topic
Targeted therapies in Melanoma, primary versus acquired resistance, reversibility
Bettina Ryll, MPNE
Tumour heterogeneity as driver of resistance to targeted therapy
Julia Boshuizen, NKI Amsterdam, Netherlands
Session- Resistance to immune therapy: an overview
John Haanen, NKI, Amsterdam, Netherlands
10.30- 11.00 Coffee
Session- Tackling resistance in Immune therapy- the latest thoughts
Immune therapies have changed Melanoma from a deadly disease to one with real hope for survival. Unfortunately, not for everyone. So this session will look into what is coming NEXT to tackle resistance to immune therapy
'Prevention is the best cure'- Cancer vaccines
Steinar Aamdal, Norway
Jean-Francois Baurain, Brussels
Increasing your chances- Neo-epitope specific TCR (T-cell receptor) gene therapy
Successful immune therapy needs the right type of neo-epitopes that allow T-cells to recognise cancer cells to destroy them. At the moment, it is chance what type of neo-epitopes a patient has- anything one can do about that?
John Haanen, NKI Amsterdam, Netherlands
Discussion and summary
12.45- 13.45 Lunch
Afternoon topic: Access to innovative new therapies
Progress in Melanoma therapies has been phenomenal- however, at the edge, where need is highest and patients are out of other options, access was and remains a constant struggle. This session will focus on how to find out which therapies are promising, how to access clinical trials abroad, what early access programs are and how they function and which role HTA (health technology assessment) plays in the access debate.
The drug development cycle in a nutshell
Roald Nystad, Norway
Accessing clinical trials abroad- a recent experience
Erik Näsman, MPNE, Sweden
Access schemes for clinical trials abroad- the Nordic experience
While most healthcare systems unfortunately still don't support participation in clinical trials abroad- some do. A positive example!
Steinar Aamdal, University of Oslo, Norway
Mind the gap- Early Access Programs for innovative therapies
Holly Lumgair, Clinigen, UK
Access, safety and benefit: the value of HTA. Developments in Europe and future view
Alric Ruther, IQWiG, Germany
16.00- 16.30 Coffee
HANDS-ON SESSION: MELANOMA ESSENTIALS: the relevant Melanoma studies
In parallel groups, we will be reading the essential Melanoma studies, annotate them and publish them for our community as THE ESSENTIAL MELANOMA LIBRARY. Material and tools provided but please bring your laptop/ tablet.
More information to come shortly on Slack
19.00 Poster competition and Reception
Present your favourite Melanoma advocacy project- past, present and future- on a poster!
20.00 Conference Dinner
Sunday, 24th March
Advocacy Day- closed program for patients and patient advocates only
please make sure you check out
Session: Advocacy- Access to adjuvant Melanoma therapies in Europe
Introduction- overview of approved adjuvant treatments for Melanoma
Koen van Elst, Stichting Melanoom, Netherlands
Kay Curtin, Ireland
Gilly Spurrier, Mélanome France
10.30- 11.00 Coffee
Melanoma Kahoot!! Test your Melanoma knowledge
Skin cancer apps in comparison
Ciprian Salceanu, Romania and Ian James, UK
Andrew Evans and colleagues
MPNE resources and update
Conference summary and closure
Bettina Ryll, MPNE
Lunch and Departure
13th March 2019 BR
Surviving Melanoma in Europe.
Access to prevention, early detection and effective treatment for all.